Major Medical Secures RMB 10 Million in Exclusive Angel Funding from Bohe Angel Fund to Advance Multimodal Thermal Physical Therapy System for Cancer

VCBeat (WeChat ID: vcbeat) has learned that Shanghai Meijie Medical Technology Co., Ltd. recently announced the completion of its angel financing round, amounting to tens of millions of yuan. The funds will be used to accelerate the research and development of an innovative multimodal tumor treatment system. This round of financing was exclusively invested by Bohe Angel Fund.

Meijie Medical focuses on the research and development of multimodal tumor thermophysical therapy systems. This system is developed based on the research achievements of the Bioheat and Mass Transfer Laboratory, which is led byLed by Dr. Xu Xuemin, Chair Professor at the School of Biomedical Engineering, Shanghai Jiao Tong University, the team has conducted nearly a decade of research on cutting-edge thermal physical therapies that stimulate the body’s anti-tumor immune response.。

Meijie Medical’s independently developed novel multimodal thermophysical therapy technology enables precise control and modulation of localized thermophysical effects on malignant tumors. This approach not only effectively treats primary tumors but also alleviates tumor-induced immunosuppression, while inducing and enhancing the body’s anti-tumor immune response, thereby effectively inhibiting distant metastasis of cancer cells. Meijie Medical is poised to become the first company globally to commercialize this novel therapeutic method.

Dr. Sun Jianqi, Chairman of Meijie Medical, stated, “The multimodal thermophysical therapy for tumors is based on the principles of thermal biology. Through localized physical treatment, it stimulates a systemic anti-tumor immune response. This represents a new paradigm in cancer treatment, and its successful application will usher in a new era for interventional tumor ablation therapies. We are delighted to partner with the Bohe Angel Fund to jointly advance the research and development of innovative therapeutic technologies, thereby serving the national health strategy!”

Ms. Liu Yuwen, Founding Partner of Bohe Angel Fund, stated as an investor in this funding round: “As a technology-driven early-stage fund focused on the healthcare sector, Bohe Angel Fund is optimistic about the application of multimodal thermal physical therapy in oncology, particularly the anti-tumor immune responses stimulated by novel therapies. Meijie Medical possesses a leading technology platform and extensive product development experience. We look forward to seeing Meijie Medical’s portfolio of products reach the market soon, enabling more cancer patients in China to access innovative treatment solutions that are safe, effective, and more cost-efficient.”

BOHE Angel Fund, established in 2015, is China’s first pharmaceutical and healthcare angel investment fund dedicated to global early-stage innovative R&D enterprises. It is committed to building China’s premier platform for identifying, nurturing, and incubating early-stage biotechnology projects and technology transfer initiatives. The fund’s seasoned investment team collaborates with an international “think tank” of top-tier scientists, entrepreneurs, and business leaders to focus on cutting-edge life science technologies urgently needed in the Chinese market. This includes the development of novel drugs targeting new mechanisms and targets in oncology, autoimmune diseases, and anti-infectives, as well as strategic investments in precision medicine innovations such as early disease screening and molecular imaging. By leveraging a deep understanding of the pathways and cycles of technology commercialization, the fund aims to enhance the success rate and growth velocity of its portfolio companies, having completed investments in over 20 projects to date.